Global Sjogren’s Syndrome Market Size study & Forecast, by Type (Primary Sjogren's Syndrome and Secondary Sjogren's Syndrome), Application (Oral, Intravenous, and Subcutaneous), and Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies, an

Global Sjogren’s Syndrome Market Size study & Forecast, by Type (Primary Sjogren's Syndrome and Secondary Sjogren's Syndrome), Application (Oral, Intravenous, and Subcutaneous), and Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies, and Others) and Regional Analysis, 2022-2029

Global Sjogren’s Syndrome Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Sjogren’s Syndrome also known as show grins is a type of autoimmune disease that affects different parts of the body that are responsible for producing fluids, like tears and spit (saliva). It mainly affects people aged between 40 to 60 years. Sjogren’s Syndrome symptoms include dry eyes & dry mouth. The increasing number of patients with Sjogren’s Syndrome and growing awareness towards Sjogren’s Syndrome as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to Reston, Virginia, USA based Sjögren’s Foundation estimates – as of 2020, autoimmune diseases affect 5 to 8% of US residents. In addition, approximately four million American citizens are affected by Sjogren’s Syndrome, with more than 2.5 million patients are steel undiagnosed. Moreover, as per The National Institutes of Health (NIH) estimates - approximately 23.5 million Americans are affected by autoimmune diseases. Also, rising growth of pharmaceuticals sector in emerging markets and growing number of R&D activities in medical sector would create lucrative growth prospectus for the market over the forecast period. However, the high treatment cost associated with Sjogren’s Syndrome impedes the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sjogren’s Syndrome Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factor such as presence of leading market players and availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising prevalence of Sjogren’s syndrome as well as growing healthcare infrastructure in the region.

Major market player included in this report are:
AbbVie Inc.
ADVANZ PHARMA Corp. Ltd
Biogen Inc
Bristol-Myers Squibb Co
Daiichi Sankyo Co. Ltd
Hikma Pharmaceuticals Plc
Johnson & Johnson
Novartis AG,
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Recent Developments in the Market:
In September 2022, Dublin Ireland based Horizon Therapeutics plc Announced Phase 2 trial of its new formulation Dazodalibep for the Treatment of Sjögren’s Syndrome. In addition, as per the score defined by the European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI), the drug has met the primary endpoint in patients with moderate-to-high systemic disease activity.

In September 2022, Switzerland based pharma major Novartis announced completion of Phase II immune disorder trial of its new formulation named remibrutinib (LOU-064).


Global Sjogren’s Syndrome Market Report Scope:
Historical DataCompanies Mentioned

AbbVie Inc.
ADVANZ PHARMA Corp. Ltd
Biogen Inc
Bristol-Myers Squibb Co
Daiichi Sankyo Co. Ltd
Hikma Pharmaceuticals Plc
Johnson & Johnson
Novartis AG,
Sanofi SA
Sun Pharmaceutical Industries Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.